A new report by XploreMR studies the growth drivers, trends, restraints, and highlights of the global sickle cell disease treatment market. Presenting exclusive insights into the market from 2017 to 2025, the report projects that the market will witness notable growth during the forecast period. Sickle cell disease causes red blood cells to become misshapen and break down, affecting the levels of hemoglobin, which leads to various other medical complications. The growth of the market is predominantly driven by advancements in the field of medicine and increasing emphasis on anemia treatment. Moreover, to change the negative perception among the masses that sickle cell disease is cancer-related, healthcare institutions are running several campaigns to raise awareness among people regarding hemoglobin deficiency. Such campaigns are expected to increase awareness and in turn, create revenue opportunities.
Efforts by Healthcare Institutions to Raise Awareness Transmutes into Revenue Prospects
The field of medicine, especially anemia, has witnessed significant advancement over the last few years, and the demand for sickle cell treatment has mushroomed in recent times. These two factors are collectively paving the way for the growth of the sickle cell disease treatment market. Sickle cell disease primarily affects the hemoglobin, which is responsible for carrying oxygen to several parts of the body. A decline in the levels of hemoglobin arises from various other complications, and hence it is vital to seek treatment for the sickle disease before the complications progress. Low levels of hemoglobin lead to weakness, shortness of breath, dizziness, headache, irregular heartbeat, and heart failure in severe cases. The demand for treating diseases related to blood plasma is subsequently increasing the demand for sickle cell disease treatment. The high incidence of the sickle disease is channeling revenue for the global sickle cell disease treatment market. Besides, healthcare institutions and medical professionals are educating people about the adverse effects of hemoglobin deficiency, which is expected to further surge the demand for the sickle cell disease treatment market in recent times.
Lack of Advanced Infrastructure Impedes Swift Adoption in Developing Economies
Although sickle cell disease treatment is on a positive growth trajectory, some factors are likely to pose a challenge to the impressive growth rate. Factors that are limiting the swift growth of sickle cell disease treatment are, the inadequacy of effective healthcare infrastructure in the Middle East & Africa, unavailability of drugs in rural areas in India, although a high number of people suffer from sickle cell disease, and lack of medical reimbursement in Europe for sickle cell anemia treatment, and high costs associated with the treatment the disease.